← Back to Search

Biological Response Modifier

Thymalfasin for Coronavirus (Ta1 Trial)

Phase 2
Waitlist Available
Research Sponsored by Inova Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether or not Thymalfasin (thymosin alpha 1 or Ta1), can help reduce the rate and severity of infection with COVID-19 in patients with end-stage renal disease (ESRD) who are on hemodialysis.

Eligible Conditions
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Reduction in documented infection with COVID-19 Reduction in infection with COVID-19
Secondary study objectives
Change in any existing comorbidities or occurrence of newly diagnosed disease
Change in lymphocyte subsets (CD4, CD8)
Duration of mechanical ventilation
+11 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Active armExperimental Treatment1 Intervention
1.6 mg thymalfasin in 1 mL subcutaneous injection twice weekly after dialysis for 8 weeks
Group II: Control armActive Control1 Intervention
Standard care

Find a Location

Who is running the clinical trial?

Inova Health SystemLead Sponsor
2 Previous Clinical Trials
860 Total Patients Enrolled
Inova Health Care ServicesLead Sponsor
72 Previous Clinical Trials
22,067 Total Patients Enrolled
Davita Clinical ResearchIndustry Sponsor
22 Previous Clinical Trials
15,241 Total Patients Enrolled
~55 spots leftby Nov 2025